Kidney injury occuring in liver failure is a historical scenario imbued w/in the parlance of medicine for centuries. In this article, I try to discuss HRS— its current concepts & challenges.
Thank you @Nephro_Sparks@DearbhlaKelly4 for helping me write this article!
1/10
#NephJC#TenPostNephJC#NephTwitter
Can just 4 doses of an SGLT2i prevent AKI after cardiac surgery? The MERCURI-2 trial put dapagliflozin to the test. But is the benefit a treat or a trick?🫀💊
Read the article 👇
https://t.co/uOIohFpnue
Mimic:
IgA Nephropathy can mimic immune complex (IC)-MPGN.
LM: Membranoproliferative (MPGN) pattern
Routine IF: inconclusive
Pronase IF: mesangial IgA 2+
EM: mesangial deposits
Dx: IgA nephropathy M1 E1 S0 T0 C0
Case was labeled primary IC-MPGN
50-yr old with hematuria and proteinuria. Serology negative.
This week we're talkin about IV Sodium Bicarbonate in the ICU.
💉Does it improve mortality, MAKE30... or just pH?
🥤The SODa-BIC study
#NephTwitter#MedTwitter
https://t.co/agCj1zh28n
Summer's almost over 😎#NephTwitter
We know you've been waiting 🏖️
#NephJC Book Club, 9/15/26 discussion!
Salama Kassab was a pharmacy student in Syria. Now she helps the wounded who flood through the doors. Set amid the Syrian Revolution, a story of hope, love & possibility.
@kidney_boy@set_fortess I have a guy diagnosed by a now retired mentor 40+ years ago, Cr and proteinuria a little higher than yours but stable
“IgAN is a heterogenous disease”
Need more tools to sort out the progressive folks from the long term stable ones
Lovely to celebrate Mass at the Basilica of Santo Nino, in Cebu, the Philippines today. It is a place very close to the heart of all Filipino people. Remembering in prayer all the Filipino people in Ireland at this time 🙏 @dublindiocese@IrishCathNews@CatholicBishops
#NephJC#TenPostNephJC.
#NephTwitter
1/10 Patients with CKD have ⬆️ CVD & bleeding risks but are often excluded from antithrombotic trials, creating a 🔑 evidence gap. Can low dose rivaroxaban safely improve CV outcomes?
https://t.co/DfGbR3wGjc
This week we're still catching up with #ERA26
The TRACK study 🛤️🩸 #NephJC#NephTwitter
Check out the VA by @DrSaiVani1
Can low dose rivaroxaban improve CV outcomes in advanced CKD?
https://t.co/E8KKlupuDs
#NephJC Consensus
From GEMRITUX, MENTOR, STARMEN, RI-CYCLO & now MAJESTY- the signal remains consistent:
✅ Anti-CD20 therapy works
✅ Remissions are durable
✅ Relapses are lower than CNIs
Check out anti-CD20 trials in pMN @CristinaDeReins👇
#NephJC#TenPostNephJC#NephTwitter
#TenPostNephJC#NephTwitter#NephJC
1/10
How often do we miss non-diabetic kidney disease (NDKD)?
🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash
@Tiff_Caza
https://t.co/0H9Rydx60J
Hypertension control remains stubbornly low in underserved communities. IMPACTS‑BP asks whether a team‑based, multi‑component approach can meaningfully improve blood pressure control and adherence in low‑income patients
🎨#VisualAbstract by @DrAkshayaJ
https://t.co/liZjXaThwl
Tigris: 15k screened, 157 enrolled, and a result that depends on how much you trust the prior #NephJC
💡Signal? Yes
🤔Confidence? Not really
✍️#NephJCshort by @CristinaDeReins
🪓Reviwed by @hswapnil and @brian_rifkin
https://t.co/BNNnUiXdqD
1/10
#NephJC#TenPostNephJC.
#NephTwitter
In 2026 💊 FDA approved sparsentan for FSGS, an endothelin A/angiotensin II receptor inhibitor.
Next up in the pipeline…transient receptor potential cation channel 6 (TRPC6) inhibitor (BI 764198) 🚰
Article 👇
https://t.co/DxVeKVlF0x
Blessings abound! The Division received various awards during the recent convention:
1. One of the Most Outstanding Fellowship Training Institution in Adult Nephrology
2. 100% passing recent Board exams
3. One of the Best performing institution in test construction
#TatakPGH
Hydralazine, a 1950s drug still used at the edges of modern care
Cheap. Available.
Signal of benefit… shadowed by decades of immune toxicity signals
58 min to #TenPostNephJC#NephJC
https://t.co/IShXIbNyle